CN102068491A - 一种治疗冠心病、心绞痛的药物组合物 - Google Patents
一种治疗冠心病、心绞痛的药物组合物 Download PDFInfo
- Publication number
- CN102068491A CN102068491A CN 201010604136 CN201010604136A CN102068491A CN 102068491 A CN102068491 A CN 102068491A CN 201010604136 CN201010604136 CN 201010604136 CN 201010604136 A CN201010604136 A CN 201010604136A CN 102068491 A CN102068491 A CN 102068491A
- Authority
- CN
- China
- Prior art keywords
- heart disease
- coronary heart
- pharmaceutical composition
- enteric coated
- weight portion
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000029078 coronary artery disease Diseases 0.000 title claims abstract description 50
- 206010002383 Angina Pectoris Diseases 0.000 title abstract description 16
- 239000003814 drug Substances 0.000 claims abstract description 35
- 235000003143 Panax notoginseng Nutrition 0.000 claims abstract description 29
- 241000180649 Panax notoginseng Species 0.000 claims abstract description 29
- 239000002994 raw material Substances 0.000 claims abstract description 21
- 239000008194 pharmaceutical composition Substances 0.000 claims description 64
- 239000002775 capsule Substances 0.000 claims description 34
- 238000011282 treatment Methods 0.000 claims description 33
- 241000237903 Hirudo Species 0.000 claims description 28
- 239000009636 Huang Qi Substances 0.000 claims description 28
- IZEKFCXSFNUWAM-UHFFFAOYSA-N dipyridamole Chemical compound C=12N=C(N(CCO)CCO)N=C(N3CCCCC3)C2=NC(N(CCO)CCO)=NC=1N1CCCCC1 IZEKFCXSFNUWAM-UHFFFAOYSA-N 0.000 claims description 27
- 229940079593 drug Drugs 0.000 claims description 26
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 18
- 238000004519 manufacturing process Methods 0.000 claims description 17
- 238000002360 preparation method Methods 0.000 claims description 11
- 210000002216 heart Anatomy 0.000 abstract description 13
- 230000000694 effects Effects 0.000 abstract description 9
- 230000000144 pharmacologic effect Effects 0.000 abstract description 7
- 238000002474 experimental method Methods 0.000 abstract description 5
- 229940126680 traditional chinese medicines Drugs 0.000 abstract description 2
- 241001061264 Astragalus Species 0.000 abstract 1
- 241000545744 Hirudinea Species 0.000 abstract 1
- 244000086363 Pterocarpus indicus Species 0.000 abstract 1
- 235000009984 Pterocarpus indicus Nutrition 0.000 abstract 1
- 235000017276 Salvia Nutrition 0.000 abstract 1
- 240000007164 Salvia officinalis Species 0.000 abstract 1
- 235000006533 astragalus Nutrition 0.000 abstract 1
- 210000004233 talus Anatomy 0.000 abstract 1
- 239000002023 wood Substances 0.000 abstract 1
- 239000003826 tablet Substances 0.000 description 31
- 238000012360 testing method Methods 0.000 description 19
- 239000008187 granular material Substances 0.000 description 15
- 239000006187 pill Substances 0.000 description 15
- 208000031225 myocardial ischemia Diseases 0.000 description 12
- 208000024891 symptom Diseases 0.000 description 8
- 230000034994 death Effects 0.000 description 7
- 206010008479 Chest Pain Diseases 0.000 description 6
- 239000004698 Polyethylene Substances 0.000 description 6
- 210000000709 aorta Anatomy 0.000 description 6
- 210000004165 myocardium Anatomy 0.000 description 6
- -1 polyethylene Polymers 0.000 description 6
- 229920000573 polyethylene Polymers 0.000 description 6
- 239000008148 cardioplegic solution Substances 0.000 description 5
- 239000008412 qishen yiqi Substances 0.000 description 5
- 206010020772 Hypertension Diseases 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical group [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 208000007536 Thrombosis Diseases 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 230000017531 blood circulation Effects 0.000 description 4
- 210000001147 pulmonary artery Anatomy 0.000 description 4
- 210000002784 stomach Anatomy 0.000 description 4
- 210000000115 thoracic cavity Anatomy 0.000 description 4
- 108010028554 LDL Cholesterol Proteins 0.000 description 3
- 206010003119 arrhythmia Diseases 0.000 description 3
- 230000006793 arrhythmia Effects 0.000 description 3
- 210000001168 carotid artery common Anatomy 0.000 description 3
- 206010012601 diabetes mellitus Diseases 0.000 description 3
- 230000035487 diastolic blood pressure Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 208000028867 ischemia Diseases 0.000 description 3
- 230000000302 ischemic effect Effects 0.000 description 3
- 210000004731 jugular vein Anatomy 0.000 description 3
- 230000002107 myocardial effect Effects 0.000 description 3
- 208000010125 myocardial infarction Diseases 0.000 description 3
- 230000000391 smoking effect Effects 0.000 description 3
- 230000035488 systolic blood pressure Effects 0.000 description 3
- 206010003211 Arteriosclerosis coronary artery Diseases 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 206010019280 Heart failures Diseases 0.000 description 2
- 206010048858 Ischaemic cardiomyopathy Diseases 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- 206010063837 Reperfusion injury Diseases 0.000 description 2
- 206010042434 Sudden death Diseases 0.000 description 2
- 210000000683 abdominal cavity Anatomy 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 230000036770 blood supply Effects 0.000 description 2
- 210000000038 chest Anatomy 0.000 description 2
- 208000035850 clinical syndrome Diseases 0.000 description 2
- 208000026758 coronary atherosclerosis Diseases 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 201000005577 familial hyperlipidemia Diseases 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000010247 heart contraction Effects 0.000 description 2
- 208000019622 heart disease Diseases 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 230000003907 kidney function Effects 0.000 description 2
- 230000003908 liver function Effects 0.000 description 2
- 230000009245 menopause Effects 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- 230000010412 perfusion Effects 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000001052 transient effect Effects 0.000 description 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 206010002660 Anoxia Diseases 0.000 description 1
- 241000976983 Anoxia Species 0.000 description 1
- 206010003225 Arteriospasm coronary Diseases 0.000 description 1
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- 208000006029 Cardiomegaly Diseases 0.000 description 1
- 206010008469 Chest discomfort Diseases 0.000 description 1
- 208000003890 Coronary Vasospasm Diseases 0.000 description 1
- 206010052895 Coronary artery insufficiency Diseases 0.000 description 1
- 208000005189 Embolism Diseases 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 208000002705 Glucose Intolerance Diseases 0.000 description 1
- 108010023302 HDL Cholesterol Proteins 0.000 description 1
- 108010010234 HDL Lipoproteins Proteins 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010021079 Hypopnoea Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 1
- 206010049418 Sudden Cardiac Death Diseases 0.000 description 1
- 208000001435 Thromboembolism Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 206010000891 acute myocardial infarction Diseases 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000007953 anoxia Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 238000010009 beating Methods 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000002168 brachiocephalic trunk Anatomy 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 201000011634 coronary artery vasospasm Diseases 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000003205 diastolic effect Effects 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000007368 endocrine function Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 230000001709 ictal effect Effects 0.000 description 1
- 210000003090 iliac artery Anatomy 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 230000009191 jumping Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 239000010813 municipal solid waste Substances 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 238000002559 palpation Methods 0.000 description 1
- 229960002275 pentobarbital sodium Drugs 0.000 description 1
- 210000003516 pericardium Anatomy 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 201000009104 prediabetes syndrome Diseases 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 210000002254 renal artery Anatomy 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 208000014221 sudden cardiac arrest Diseases 0.000 description 1
- 208000008203 tachypnea Diseases 0.000 description 1
- 206010043089 tachypnoea Diseases 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000001732 thrombotic effect Effects 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 208000003663 ventricular fibrillation Diseases 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
组别 | 例数 | 显效 | 有效 | 无效 | 总有效率% |
对照组 | 40 | 8 | 19 | 13 | 67.5 |
治疗组 | 40 | 12 | 28 | 0 | 100 |
组别 | 例数 | 显效 | 有效 | 无效 | 总有效率% |
对照组 | 40 | 5 | 15 | 20 | 50 |
治疗组 | 40 | 9 | 19 | 12 | 70 |
Claims (7)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2010106041365A CN102068491B (zh) | 2010-12-24 | 2010-12-24 | 一种治疗冠心病、心绞痛的药物组合物 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2010106041365A CN102068491B (zh) | 2010-12-24 | 2010-12-24 | 一种治疗冠心病、心绞痛的药物组合物 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102068491A true CN102068491A (zh) | 2011-05-25 |
CN102068491B CN102068491B (zh) | 2012-06-20 |
Family
ID=44027369
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2010106041365A Active CN102068491B (zh) | 2010-12-24 | 2010-12-24 | 一种治疗冠心病、心绞痛的药物组合物 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN102068491B (zh) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104056199A (zh) * | 2014-06-26 | 2014-09-24 | 青岛市市立医院 | 一种治疗心脑血管疾病的中药 |
CN108310356A (zh) * | 2018-05-08 | 2018-07-24 | 薛振宇 | 一种治疗血管性疾病的药物组合物及其制备方法 |
CN110522787A (zh) * | 2018-05-24 | 2019-12-03 | 郑州恩欧生物科技有限公司 | 一氧化氮供体中药复方制剂及其制备方法和应用 |
CN111544419A (zh) * | 2020-06-11 | 2020-08-18 | 王文龙 | 冠心病外用贴膏及其贴膜 |
CN114848744A (zh) * | 2022-04-26 | 2022-08-05 | 杭州市中医院 | 一种治疗气虚血瘀型冠心病的中药组合物及其制备方法 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1375316A (zh) * | 2002-02-07 | 2002-10-23 | 天津天士力制药股份有限公司 | 治疗冠心病心绞痛的中药制剂及其制备方法 |
CN101433584A (zh) * | 2008-12-12 | 2009-05-20 | 上海禾丰制药有限公司 | 治疗气虚血瘀型冠心病的药物组合物及其制备方法 |
-
2010
- 2010-12-24 CN CN2010106041365A patent/CN102068491B/zh active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1375316A (zh) * | 2002-02-07 | 2002-10-23 | 天津天士力制药股份有限公司 | 治疗冠心病心绞痛的中药制剂及其制备方法 |
CN101433584A (zh) * | 2008-12-12 | 2009-05-20 | 上海禾丰制药有限公司 | 治疗气虚血瘀型冠心病的药物组合物及其制备方法 |
Non-Patent Citations (2)
Title |
---|
《中国中医急症》 20090228 龙铟等 益气活血法治疗冠心病心绞痛研究近况 第271-272页 1-7 第18卷, 第2期 2 * |
《中西医结合心脑血管病杂志》 20080229 康善平 益气活血法治疗冠心病研究进展 第193-194页 1-7 第6卷, 第2期 2 * |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104056199A (zh) * | 2014-06-26 | 2014-09-24 | 青岛市市立医院 | 一种治疗心脑血管疾病的中药 |
CN108310356A (zh) * | 2018-05-08 | 2018-07-24 | 薛振宇 | 一种治疗血管性疾病的药物组合物及其制备方法 |
CN110522787A (zh) * | 2018-05-24 | 2019-12-03 | 郑州恩欧生物科技有限公司 | 一氧化氮供体中药复方制剂及其制备方法和应用 |
CN110522787B (zh) * | 2018-05-24 | 2021-11-12 | 郑州恩欧生物科技有限公司 | 一氧化氮供体中药复方制剂及其制备方法和应用 |
CN111544419A (zh) * | 2020-06-11 | 2020-08-18 | 王文龙 | 冠心病外用贴膏及其贴膜 |
CN111544419B (zh) * | 2020-06-11 | 2023-06-23 | 王文龙 | 冠心病外用贴膏及其贴膜 |
CN114848744A (zh) * | 2022-04-26 | 2022-08-05 | 杭州市中医院 | 一种治疗气虚血瘀型冠心病的中药组合物及其制备方法 |
CN114848744B (zh) * | 2022-04-26 | 2023-08-15 | 杭州市中医院 | 一种治疗气虚血瘀型冠心病的中药组合物及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN102068491B (zh) | 2012-06-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102068491B (zh) | 一种治疗冠心病、心绞痛的药物组合物 | |
CN101293082B (zh) | 一种同时改善骨骼肌功能的抗心衰药物组合物及其制备方法 | |
CN103099854B (zh) | 肾康注射液在制备防治心脑血管疾病药物中的应用 | |
CN104147346B (zh) | 一种治疗冠脉弥漫性病变心绞痛的中药复方 | |
CN101342238B (zh) | 一种治疗心脑血管疾病的药物组合物 | |
CN104740054B (zh) | 一种防治心肌缺血的药物组合物及其制备方法和用途 | |
CN103908490A (zh) | 一种治疗心肌梗塞和心血管疾病的纯植物中药制剂及制备方法 | |
CN110292607B (zh) | 治疗高血压病并发左心室肥厚的中药组合物及制备方法 | |
CN101032534B (zh) | 救必应总皂苷的制备方法及应用 | |
CN102068520A (zh) | 一种治疗心脑血管疾病的中药组合物及其制备方法 | |
CN102309561B (zh) | 一种用于预防和治疗痛风性关节炎及高尿酸血症的药物组合物 | |
CN104667143A (zh) | 一种治疗冠心病的中药汤剂 | |
CN100502937C (zh) | 一种治疗心血管疾病的中药组合物及其制备方法 | |
CN113559206B (zh) | 一种防治心房颤动的复方中药 | |
CN102836320B (zh) | 治疗快速型心律失常的中药丸 | |
CN102309675B (zh) | 一种中药组合物在制备治疗病态窦房结综合征药物中的应用 | |
CN102091109A (zh) | 一种治疗心脑血管疾病的药物组合物 | |
CN105770520A (zh) | 一种用于治疗冠心病的药物制剂及其用途 | |
CN105168653A (zh) | 一种用于治疗冠心病的中药组合物 | |
CN105596505A (zh) | 一种治疗心气虚劳型心律失常的中药 | |
CN101559162B (zh) | 一种中药组合物在制备治疗缓慢型心律失常药物中的应用 | |
CN115177669A (zh) | 一种具有治疗心肌桥功效的中药组合物及其应用 | |
CN105012428B (zh) | 一种降血压的中药组合物及其制备方法 | |
CN104116794B (zh) | 一种辅助治疗肥胖相关性高血压病的中药 | |
CN101485768A (zh) | 花椒枝药用物质的制备技术及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C53 | Correction of patent of invention or patent application | ||
CB02 | Change of applicant information |
Address after: Cao Jia Dian 400802 Chongqing city Wansheng District East Qingxi Bridge Applicant after: CHONGQING DUOPUTAI PHARMACEUTICAL Co.,Ltd. Address before: Cao Jia Dian 400802 Chongqing city Wansheng District East Qingxi Bridge Applicant before: CHONGQING SHIZHENGE PUSHENG PHARMACEUTICAL Co.,Ltd. |
|
COR | Change of bibliographic data |
Free format text: CORRECT: APPLICANT; FROM: CHONGQING SHIZHEN'GE PUSHENG PHARMACEUTICAL CO., LTD. TO: CHONGQING DUOPUTAI PHARMACEUTICAL CO., LTD. |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CP03 | Change of name, title or address | ||
CP03 | Change of name, title or address |
Address after: Cao Jia Dian 400800 Chongqing city Wansheng District East Qingxi Bridge Patentee after: CHONGQING DUOPUTAI PHARMACEUTICAL Co.,Ltd. Address before: Cao Jia Dian 400802 Chongqing city Wansheng District East Qingxi Bridge Patentee before: Chongqing Duoputai Pharmaceutical Co.,Ltd. |
|
TR01 | Transfer of patent right |
Effective date of registration: 20240117 Address after: No. 303-7, Qingxi Bridge, Donglin Street, Wansheng Economic Development Zone, Qijiang District, Chongqing, 400800 Patentee after: Chongqing Duoputai Pharmaceutical Technology Co.,Ltd. Address before: 400800 Donglin Qingxi bridge in Wansheng District, Chongqing Patentee before: CHONGQING DUOPUTAI PHARMACEUTICAL Co.,Ltd. |
|
TR01 | Transfer of patent right |